Reik & Co’s Moderna MRNA Stock Holding History

Reik & Co’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$268K	Buy	+3,830	New	+$198K	0.07%	53
2024 Q4	–	Sell	-4,898	Closed	-$327K	–	57
2024 Q3	$327K	Buy	4,898 +120	+3%	+$11K	0.08%	47
2024 Q2	$567K	Sell	4,778 -2	-0%	-$253	0.15%	37
2024 Q1	$509K	Hold	4,780	–	–	0.13%	40
2023 Q4	$475K	Hold	4,780	–	–	0.13%	39
2023 Q3	$494K	Buy	4,780 +500	+12%	+$55.8K	0.14%	38
2023 Q2	$520K	Hold	4,280	–	–	0.14%	40
2023 Q1	$657K	Sell	4,280 -105	-2%	-$17.3K	0.19%	38
2022 Q4	$788K	Sell	4,385 -650	-13%	-$106K	0.23%	33
2022 Q3	$595K	Buy	5,035 +400	+9%	+$60.7K	0.19%	37
2022 Q2	$662K	Hold	4,635	–	–	0.19%	36
2022 Q1	$798K	Buy	4,635 +1,400	+43%	+$236K	0.2%	37
2021 Q4	$822K	Buy	3,235 +885	+38%	+$259K	0.2%	35
2021 Q3	$904K	Buy	2,350 +350	+18%	+$129K	0.23%	33
2021 Q2	$470K	Hold	2,000	–	–	0.12%	44
2021 Q1	$262K	Buy	+2,000	New	+$290K	0.07%	48

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Reik & Co's MRNA Position: Q2 2026 in Review

Reik & Co opened a new position in Moderna (MRNA) in Q2 2026: 3,830 shares worth $268K. The stake represents 0.07% of the portfolio and ranks #53 among its holdings. This is a return to the name: Reik & Co previously reported a position in MRNA as recently as Q3 2024.

Reik & Co first reported a position in MRNA in Q1 2021 and has held it in 16 quarters since. The position peaked at $904K in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Reik & Co held 3,830 shares of Moderna worth $268K as of Q2 2026.
Moderna was a new Reik & Co position in Q2 2026.
Moderna made up 0.07% of Reik & Co's portfolio in Q2 2026, its #53 holding.
Reik & Co first reported a position in Moderna in Q1 2021 and has held it in 16 quarters since.
Reik & Co's Moderna position peaked at $904K in Q3 2021.
782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Reik & Co's 13F filing for Q2 2026, filed 10 Aug 2026.